Carcinoma in situ of the urinary bladder

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Carcinoma in situ of the urinary bladder is a wide spread urological malignancy with unpredictable clinical course and prognosis. While diagnostic modalities develop the treatment and follow-up regimen recommended have been standardized.

Full Text

Restricted Access

About the authors

Igor Alekseevich Korneyev

St.-Petersburg State Medical University named after acad. I. P. Pavlov

Email: iakorneyev@yandex.ru
doctor of medical science, professor. Department of Urology

Dmitriy Borisovich Batmaev

St.-Petersburg State Medical University named after acad. I. P. Pavlov

Email: iakorneyev@yandex.ru
student. St.-Petersburg State Medical University named after acad. I. P. Pavlov

References

  1. Аль-Шукри С. Х., Данильченко Д. И., Корнеев И. А., Аль-Шукри А. С. Прогностическая ценность флуоресцентной цистоскопии с использованием 5-аминолевулиновой кислоты у больных раком мочевого пузыря // Нефрология. 2005. Т. 9. № 4. С. 80–84.
  2. Аль-Шукри С. Х., Корнеев И. А., Кассем А. М., Козлов В. В. Применение адъювантной внутрипузырной иммунотерапии вакциной БЦЖ «Имурон» и прогноз у больных с поверхностными переходноклеточными карциномами мочевого пузыря // Тезисы докладов четвертого международного урологического симпозиума «Диагностика и лечение рака мочевого пузыря». Нижний Новгород. 2005. C. 10.
  3. Аль-Шукри С. Х., Эмануэль В. Л., Корнеев И. А. и др. Прогностическая ценность цитологического исследования осадка мочи у больных раком мочевого пузыря // Нефрология. 2006. № 10 (2). C. 101–104.
  4. Ткачук В. Н., Данильченко Д. И., Аль-Шукри А. С. Место оптико-когерентной томографии в диагностике рака мочевого пузыря // Урология. 2009. № 2 C.42–44.
  5. Berger A. P., Steiner H., Stenzl A. et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study // Urology. 2003. № 61. P. 338–341.
  6. De Reijke T. M., Kurth K. H., Sylvester R. J. et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer Genito-Urinary Group phase III trial (30906) // J. Urol. 2005. № 173. P. 405–409.
  7. D’Hallewin M. A., Bezdetnaya L., Guillemin F. Fluorescence detection of bladder cancer: a review // Eur. Urol. 2002. № 42. P. 417–425.
  8. Epstein J. I., Amin M. B., Reuter V. R., Mostofi F. K., the Bladder Consensus Conference Committee. The World Health Organization / International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder // Am. J. Surg. Path. 1998. № 22. P. 1435–1448.
  9. Glas A. S., Roos D., Deutekom M., Zwinderman A. H., Bossuyt P. M. M., Kurth K. H. Tumor markers in the diagnosis of primary bladder cancer. A systematic review // J. Urol. 2003. № 169. P. 1975–1982.
  10. Jakse G. et al., members of the EORTC GU Group. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861 // Eur. Urol. 2001. № 40. P. 144–150.
  11. Kaasinen E., Wijkstrom H., Malmstrom P. U. et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study // Eur. Urol. 2003. № 43 P. 637–645.
  12. Kurth K. H., Schellhammer P. F., Okajima E. et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra // Int. J. Urol. 1995. № 2 (Suppl 2). P. 8–22.
  13. Lamm D. L. Carcinoma in situ // Urol. Clin. N. Am. 1992. № 19. P. 499–508.
  14. Lamm D. L., Herr H. W., Jakse G. et al. Updated concepts and treatment of carcinoma in situ // Urol Oncol. 1998. № 4. P. 130–138.
  15. Lamm D. L., van der Meijden A. P. M., Akaza H. et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? // Int. J. Urol. 1995. № 2 (Suppl 2). P. 23–25.
  16. Lamm D. L., van der Meijden A. P. M., Morales A. et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer // J. Urol. 1992. № 147. P. 596–600.
  17. Lopez-Beltran A., Bassi P. F., Pavone-Macaluso M., Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis // Eur. Urol. 2004. № 45. P. 257–266.
  18. O’Donnell M. A. et al., the National Bacillus Calmette-Guerin / Interferon phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2b for superficial bladder cancer // J. Urol. 2004. № 172. P. 888–893.
  19. Sarosdy M. F., Manyak M. J., Sagalowsky A. I. et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin // Urology. 1998. № 51. P. 226–231.
  20. Sharkey F. E., Sarosdy M. F. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ // J. Urol. 1997. № 157. P. 68–70.
  21. Solsona E., Iborra I., Dumont R. et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer // J. Urol. 2000. № 164. P. 685–689.
  22. Solsona E., Iborra I., Ricos J. V. et al. Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management // Urology. 1997. № 49. P. 347–352.
  23. Steinberg G., Bahnson R., Brosman S. et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder // J. Urol. 2000. № 163. P. 761–767.
  24. Witjes J. A. Bladder carcinoma in situ in 2003: state of the art // Eur. Urol. 2004. № 45. P. 142–146.
  25. Zaak D., Hungerhuber E., Schneede P. et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions // Cancer. 2002. № 95. P. 1234–1238.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Korneyev I.A., Batmaev D.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies